The positive CHMP opinion is both timely and expected. The next step is a Q3 European approval allowing Calliditas partner Stada to launch Kinpeygo in Europe. We can also look forward to the Part B readout in early 2023, which is likely to support both sales and the process of converting the conditional approval to unconditional approval.